April 3 (Reuters) - Pardes Biosciences Inc said on Monday it will suspend further clinical development of its experimental drug pomotrelvir, after it did not meet the main goal of a mid-stage trial for treating COVID-19. (Reporting by Raghav Mahobe in Bengaluru; Editing by Krishna Chandra Eluri)
Pardes Biosciences, Inc.
Equities
PRDS
US69945Q1058
Biotechnology & Medical Research
1st Jan change | Capi. | |
---|---|---|
+33.05% | 4.95TCr | |
+1.99% | 4.26TCr | |
+49.11% | 4.25TCr | |
-4.22% | 2.91TCr | |
+12.08% | 2.66TCr | |
-22.51% | 1.86TCr | |
+8.41% | 1.32TCr | |
+30.32% | 1.25TCr | |
+24.03% | 1.21TCr |